GSK plc Sponsored ADR (GSK)
GSK: Disproportionately discounted, but earnings beat shows signs of reappraisal
Shore Capital is sticking with its upbeat view on GSK PLC (LSE:GSK, NYSE:GSK), calling the stock “disproportionately discounted” after first-quarter numbers surpassed expectations and guidance was held, despite headwinds from foreign exchange and political noise around drug pricing. The key beat came on earnings, with core EPS up 5% at constant exchange rates to 44.9p, a full 10% ahead of consensus.
GSK (GSK) Q1 Earnings Surpass Estimates
GSK (GSK) came out with quarterly earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.08 per share. This compares to earnings of $1.09 per share a year ago.
GSK jumps 4% as earnings beat boosts confidence
GSK PLC (LSE:GSK, NYSE:GSK) shares rose 4% on Tuesday, adding £2.6 billion to its market value, after the drugmaker delivered better-than-expected first-quarter results and reiterated full-year guidance. The FTSE 100 group reported core earnings per share of 44.9p, 10% ahead of consensus, thanks to stronger operating leverage and a robust margin of 33.7%.
GSK beats earnings forecasts despite weaker vaccine sales
GSK PLC (LSE:GSK, NYSE:GSK) reported earnings ahead of expectations and kept full-year guidance intact, even though sales of vaccines softened. The FTSE 10-listed drugmaker reported a 6.1% fall in vaccine sales to £2.10 billion, which was almost in line with the $2.11 billion average City forecast.
GSK Sales, Profit Rise on Boost from Cancer Drugs
The British pharmaceutical giant said that its first-quarter sales rose to 7.52 billion pounds from 7.36 billion pounds the year prior.
GSK to Report First-Quarter Earnings: Is a Beat in Store?
We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.
GSK update brings US vaccine exposure into spotlight, as sceptic RFK Jr looms
First-quarter results from GSK PLC (LSE:GSK, NYSE:GSK) will focus on commentary around the outlook, including interpretation of US policy changes under vaccine sceptic health secretary Robert Kennedy Jnr, including recent vaccine performance in the US and China. Weakness in the first quarter is anticipated in the US from GSK's key vaccine franchises, RSV vaccine Arexvy and shingles vaccine Shingrix.
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UK approves combination therapies of GSK's blood cancer drug Blenrep
GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities for the treatment of a type of blood cancer in adults who had received at least one other therapy previously.
Here's Why GSK (GSK) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP
The U.S. CDC's Advisory Committee recommends the use of GSK's pentavalent Penmenvy vaccine as part of the adolescent meningococcal vaccination schedule.
GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59
The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high risk of severe RSV disease.
